In biopharmaceutical deal-making, 2020 was a busy year on both the M&A and partnering front. Not surprisingly, the COVID-19 pandemic drove a significant amount of collaborations during the year, pushing infectious disease past cancer as the therapeutic area with the greatest deal volume. While infectious disease yielded 371 alliance deals during 2020, according to Biomedtracker, COVID-19 was the focus of 204 of those deals.
The industry recorded roughly 50% more biopharma M&A transactions during 2020 compared to the prior year, but those deals yielded...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
